值得关注的生物技术股票：Halozyme在盈利推动爆发后现在可以行动了-动脉网

Biotech Stocks To Watch: Halozyme Actionable Now After Earnings-Fueled Breakout

IBDDIGITAL 等信源发布 2024-05-10 13:09



可切换为仅中文







Among top biotech stocks to watch, Halozyme Therapeutics (HALO) is trading inside a buy zone after a breakout.

在值得关注的顶级生物科技股中，Halozyme Therapeutics（HALO）在突破后在买入区内交易。

十

San Diego-based Halozyme is the maker of the popular ENHANZE technology, which facilitates rapid high-dose, high-volume subcutaneous (under the skin) drug delivery. The technology is utilized in a variety of popular drugs, such as lung cancer treatment Tecentriq SC.

总部位于圣地亚哥的Halozyme是流行的ENHANZE技术的制造商，该技术有助于快速高剂量，大容量皮下（皮下）药物输送。该技术被用于多种流行药物，例如肺癌治疗Tecentriq SC。

Drug delivery mechanisms are of utmost importance when it comes to drug efficiency. This subcutaneous form has many positives, including convenience, shorter treatment and it doesn't require poking a needle into veins.

就药物效率而言，药物输送机制至关重要。这种皮下形式有许多优点，包括方便，治疗时间短，不需要将针扎入静脉。

This has provided the company with meaningful sources of revenue, as it earns the majority of its revenue from royalties from other companies using the ENHANZE technology.

这为该公司提供了有意义的收入来源，因为它的大部分收入来自使用ENHANZE技术的其他公司的版税。

In 2023, the biotech stock saw earnings growth of 25%, from $2.22 a share the year prior to $2.77. Meanwhile, revenue growth has averaged 24% over the past four quarters. Analysts forecast 2024 EPS of $3.65, representing an increase of 32% year-over-year.

2023年，生物技术股的每股收益增长了25%，较上年的2.77美元增长了2.22美元。与此同时，过去四个季度收入平均增长24%。分析师预测2024年每股收益为3.65美元，同比增长32%。

On May 7, the company reported earnings and sales results that were mixed. Earnings of 79 cents a share exceeded expectations for 70 cents. This represented a jump of 68% year over year. But revenue of $195.9 million missed expectations for $201.5 million. Still, it represented growth of 21%.

5月7日，该公司公布的收益和销售结果喜忧参半。每股收益79美分，超出预期70美分。这意味着同比增长了68%。但1.959亿美元的收入超出了2.015亿美元的预期。尽管如此，它仍代表着21%的增长。

Biotech Stocks To Watch: Halozyme By The Numbers

值得关注的生物科技股：Halozyme

On May 8, Halozyme scored a breakout following the earnings report. The stock swung from an 8.6% gain at its peak to a 1.9% gain at its close that day. Normally, a close within the lower half of the day's intraday bar signals weakness. But the stock managed to push higher in the following days and remains inside a 5% buy zone..

5月8日，Halozyme在财报发布后取得突破。该股从峰值时的8.6%上涨到当天收盘时的1.9%。正常情况下，日内横线下半部的收盘意味着疲软。但该股在接下来的几天里成功推高，并保持在5%的买入区间内。。

Shares are trading above a 42.64 cup-with-handle entry and inside the buy zone, which extends to 44.77.

股票在42.64杯上方交易，有手柄进入，在买入区内，买入区延伸至44.77。

Other positives for the stock include an B+ Accumulation/Distribution Rating and a growing number of funds that own the stock. The number of funds reached 756 in the most recent quarter, up from 722 in the June, 2023-ended quarter.

该股的其他利好因素包括B+累积/分配评级以及拥有该股的基金数量不断增加。最近一个季度，基金数量达到756只，高于2023年6月结束的一个季度的722只。

The industry group itself, which contains over 750 names, currently ranks No. 28 out of IBD's 197 groups. This is shows group leadership for biotech stocks.

该行业集团本身拥有750多个名称，目前在IBD的197个集团中排名第28位。这显示了生物科技股的集团领导地位。